secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001764013-23-000159
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports positive initial Phase 2 data for batoclimab in Graves' disease; IgG reduction up to 87%
--------------------------------------------------------------------------------

- Initial cohort in Phase 2 trial exceeded 50% response rate; response defined as normalization of T3/T4 without increasing ATD dose.
- 680 mg SC batoclimab showed IgG reduction up to 87% (mean 81%) after 12 weeks; 340 mg produced lower IgG reductions.
- Dose response observed on anti-TSHR autoantibodies and clinical parameters including ATD dose reduction/discontinuation.
- Batoclimab generally well tolerated with no new safety signals.
- CEO says intent to focus future Graves' development on IMVT-1402, with plans announced later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000159/0001764013-23-000159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000159/imvt-20231220.htm
  HTML page:      https://secwatch.observer/filing/0001764013-23-000159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer